Tilch, Marie-Kristin http://orcid.org/0000-0003-2395-052X
Schranz, Melanie
Moringlane, Alice
Theobald, Matthias
Hess, Georg
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Received: 30 November 2021
Accepted: 11 April 2022
First Online: 29 April 2022
Declarations
:
: Both clinical studies were performed in accordance with the 1964 Declaration of Helsinki and its later amendments. The local ethics committee approved both study protocols (approval number Marie-Kristin Tilch 837.269.15 (10037), approval number Alice Moringlane 837.277.13 (8962-F)). All study participants gave written informed consent.
: Informed consent was obtained from all individual participants included.
: All participants consented for publication.
: The authors declare the following competing interest:Marie-Kristin Tilch, Alice Moringlane, and Melanie Schranz have no conflicts of interest to declare. Matthias Theobald received honoraria from Janssen Pharmaceuticals and is on an advisory board for Novartis AG. Georg Hess reported funding by Roche, Janssen Pharmaceuticals, Celgene, and Gilead and speaker’s or advisory honoraria from Janssen, Roche, Celgene, Gilead, Novartis, MorphoSys, AbbVie, and Astra.